Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Karyopharm Therapeutics (KPTI) PT Raised to $21 at Wedbush
May 1, 2018 9:59 AM EDTWedbush raised its price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $21.00 (from $19.00) while maintaining a Outperform rating.
Analyst David Nierengarten commented, "Topline results from STORM met our expectations and should be sufficient to support accelerated approval (AA) for selinexor plus dex in... More
Karyopharm Therapeutics (KPTI) PT Raised to $24 at RBC Capital; 'We Would Be Buyers'
May 1, 2018 7:58 AM EDTRBC Capital raised its price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $24.00 (from $22.00) while maintaining a Outperform rating.
Analyst Brian Abrahams commented, "Expanded ph.II STORM data for selinexor in MM looks to have met the ORR/DOR bar for confirming its likely... More
Karyopharm Therapeutics (KPTI) to Resume Trading at 4:35 pm ET
April 30, 2018 4:16 PM EDTKaryopharm Therapeutics (NASDAQ: KPTI) to Resume Trading at 4:35 pm ET
... More